Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

SOLENO Aktie

>SOLENO Aktienkurs

41.82 EUR -1.7% (Tradegate)

Ask: 42.38 EUR / 450 Stück

Bid: 41.94 EUR / 450 Stück

Tagesumsatz: 84 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

SOLENO Aktie über LYNX handeln

Intraday

1 Jahr

>SOLENO Performance

1 Woche: -5,0%

1 Monat: -2,6%

3 Monate: +0,2%

6 Monate: -37,2%

1 Jahr: -8,3%

laufendes Jahr: -1,7%

>SOLENO Aktie

Name:

SOLENO THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8342033094 / A3DS0P

Symbol/ Ticker:

6XC (Frankfurt) / SLNO (NASDAQ)

Kürzel:

FRA:6XC, ETR:6XC, 6XC:GR, NASDAQ:SLNO

Index:

Webseite:

https://soleno.life/

Profil:

Soleno Therapeutics Inc. is a biopharmaceutical co..
>Volltext..

Marktkapitalisierung:

2264.11 Mio. EUR

Unternehmenswert:

1883.93 Mio. EUR

Umsatz:

84.05 Mio. EUR

EBITDA:

-70.07 Mio. EUR

Nettogewinn:

-66.82 Mio. EUR

Gewinn je Aktie:

-1.56 EUR

Schulden:

44.86 Mio. EUR

Liquide Mittel:

210.1 Mio. EUR

Operativer Cashflow:

-22.11 Mio. EUR

Bargeldquote:

Umsatzwachstum:

Gewinnwachstum:

43.25%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SOLENO

Letzte Datenerhebung:

16.12.25

>SOLENO Kennzahlen

Aktien/ Unternehmen:

Aktien: 53.71 Mio. St.

Frei handelbar: 91.7%

Leerverk. Aktien: 16.93%

Rückkaufquote: -9.19%

Mitarbeiter: 92

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 134.91%

Bewertung:

KGV: -

KGV lG: 263.25

KUV: 27.79

KBV: 5.3

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 97.12%

Gewinnmarge: -79.5%

Operative Marge: -85.4%

Managementeffizenz:

Gesamtkaprendite: -17.5%

Eigenkaprendite: -20.66%

>SOLENO Peer Group

Es sind 599 Aktien bekannt.

>SOLENO Chart & Kurs - NASDAQ

>SOLENO News

16.12.25 - 18:24	Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses (PR Newswire)
	SAN DIEGO, Dec. 15, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to......

11.12.25 - 16:06	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

04.12.25 - 23:27	Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses (PR Newswire)
	SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to......

04.12.25 - 01:36	Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? (Fool)
	Soleno just turned profitable for the first time—right as a major fund made its move....

03.12.25 - 22:09

Soleno Therapeutics Announces the Passing of Board Member William G. Harris (GlobeNewswire EN)

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. “Bill” Harris, who served as a valued member of Soleno's Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee....

20.11.25 - 16:06	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

11.11.25 - 13:15	Soleno Therapeutics announces entry into $100M accelerated share repurchase agreement (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 13:03

Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement (GlobeNewswire EN)

REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement (“ASR”) with Jefferies LLC (“Jefferies”) to repurchase $100 million of Soleno's common stock....

10.11.25 - 20:48	INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm (PR Newswire)
	NEWTOWN, Pa., Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO), resulting from allegations of providing potentially misleading business......

08.11.25 - 01:31	SLNO INVESTIGATION ALERT: Investigation Launched into Soleno Therapeutics, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm (PR Newswire)
	SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ: SLNO) focused on whether Soleno and certain of its top executives made false and/or misleading......

07.11.25 - 16:06	Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman (PR Newswire)
	SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ -- On November 5, 2025, investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of their shares tumble $18.78 (-28%) after the company reported disappointing information......

05.11.25 - 19:57	Soleno plunges despite Q3 beat as demand for Vykat XR cools (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 07:51	Soleno signals continued VYKAT XR market growth with net revenue doubling to $66M as European expansion advances (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.10.25 - 13:03	Soleno Therapeutics to Participate in Upcoming November Conferences (GlobeNewswire EN)
	REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November:...

21.10.25 - 14:03

Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET (GlobeNewswire EN)

REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Tuesday, November 4, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations....

21.10.25 - 03:12	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued......

18.10.25 - 16:06	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

16.10.25 - 20:06	Soleno Therapeutics gains amind renewed takeover speculation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.10.25 - 02:03	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued......

13.10.25 - 20:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram